Mineralys Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the three months ended December 31, 2025, four of our directors and officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted orterminated a contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules). The material terms of these Rule 10b5-1 trading arrangements are described below:
| Name and Title | Action Taken | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Number of Securities |
|---|---|---|---|---|---|
| David Rodman, M.D., Chief Medical Officer | Adoption October 6, 2025 | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | January 2, 2026 to December 21, 2026 | (1) |
| Alexander Gold, M.D., Director | Adoption October 14, 2025 | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | January 8, 2026 to December 31, 2026 | (2) |
| Jon Congleton, Chief Executive Officer and Director | Adoption December 30, 2025 | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | March 31, 2026 to March 31, 2027 | (3) |
| Daphne Karydas, Director | Adoption December 30, 2025 | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | March 13, 2026 to March 12, 2027 | (4) |
(1)Dr. Rodman’s Rule 10b5-1 trading arrangement provides for the sale of up to (i)65,838 shares of common stock that are currently outstanding and (ii)420,707 shares of common stock subject to a stock option award granted to Dr. Rodman that vests ratably over time.
(2)Dr. Gold’s Rule 10b5-1 trading arrangement provides for the sale of up to 18,333 shares of common stock subject to a stock option award granted to Dr. Gold that vests ratably over time.
(3)Mr. Congleton’s Rule 10b5-1 trading arrangement provides for the sale of up to 300,000 shares of common stock that are currently outstanding.
(4)Mr. Karydas’ Rule 10b5-1 trading arrangement provides for the sale of up to 36,000 shares of common stock subject to a stock option award granted to Ms. Karydas that vests ratably over time.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.